$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
How long does it take for cabergoline to take effect and changes in blood prolactin?
2026-02-01 22:25:32
Check Details
Possible reactions and treatment methods after discontinuation of momelotinib
2026-02-01 22:25:32
Check Details
How long can the efficacy of Bikken Pronol Tablets (Bituvi) last and the observation of long-term medication effects
2026-02-01 22:25:32
Check Details
Detailed description of contraindications for decarvatinib
2026-02-01 22:25:32
Check Details
Evaluation of the actual efficacy of Apremilast (Otelac) in the treatment of psoriatic arthritis
2026-02-01 22:25:32
Check Details
Valganciclovir (valganciclovir) medical insurance reimbursement status and patient out-of-pocket cost reference
2026-02-01 22:25:32
Check Details
Why are some patients not recommended to take ponatinib?
2026-02-01 22:25:32
Check Details
Advantages and clinical prospects of safinamide tablets (Sidac), a new Parkinson’s drug to be launched soon
2026-02-01 22:25:32
Check Details
Analysis of domestic availability and market sales prospects of Tarlatamab-Imdelltra in 2025
2026-02-01 22:25:32
Check Details
Telisotuzumab-EMRELIS common side effects and long-term medication safety and risk tips
2026-02-01 22:25:32
Check Details
Common side effects, risks and precautions of tovorafenib
2026-02-01 22:25:32
Check Details
Whether vorasidenib-VORANIGO has been included in medical insurance and details of policy updates and reimbursement conditions
2026-02-01 22:25:32
Check Details
1
2
...
2335
2336
2337
2338
2339
2340
2341
...
10240
10241
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Sotorasib (Lumakras): Indications, Dosing, Safety and the Next-Gen KRAS G12C Landscape
2
Momelotinib for Myelofibrosis: Spleen Response, Symptom Improvement and Efficacy Monitoring
3
Pirtobrutinib and Risks of Atrial Fibrillation and Bleeding: Mechanism, Data Interpretation and Monitoring
4
Weight Gain and Edema Management, Monitoring of Repotrectinib (Augtyro) During Treatment
5
Ixazomib (Ninlaro) Dosing Schedule, Missed Dose Management and Cycle Planning in 28‑Day Regimen
6
Ponatinib in the PACE Phase II Trial: Response Data in Resistant CML and Ph+ ALL
7
Selumetinib for NF1-Related Plexiform Neurofibromas: Time to Response and Response Assessment
8
How to Take Tucatinib (Tukysa): Dosing Schedule, Combination Use & Missed Dose Guidance
9
Ganaxolone Common Side Effects: Somnolence, Sedation and Safety Notes
10
Baxdrostat: Efficacy and Safety of a Novel Aldosterone Synthase Inhibitor
11
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
12
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment